CGON (CG Oncology) Pre-Tax Income : $-88.04 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. CG Oncology's pretax income for the three months ended in Dec. 2024 was $-31.80 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-88.04 Mil. CG Oncology's pretax margin was -6,973.25%.

During the past 4 years, CG Oncology's highest Pretax Margin was -123.95%. The lowest was -23826.96%. And the median was -13143.02%.

CG Oncology Pre-Tax Income Historical Data

The historical data trend for CG Oncology's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Pre-Tax Income Chart

CG Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Pre-Tax Income

-12.84

-35.44

-48.61

-88.04

CG Oncology Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial					-16.56	-16.93	-18.90	-20.41	-31.80

Competitive Comparison of CG Oncology's Pre-Tax Income

For the Biotechnology subindustry, CG Oncology's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where CG Oncology's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

CG Oncology Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

CG Oncology's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-114.666	+	0.003	+	0	+	26.624	+	0
	=	-88.04

CG Oncology's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-38.049	+	0.006	+	0	+	6.245	+	0
	=	-31.80

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-88.04 Mil.

CG Oncology (NAS:CGON) Pre-Tax Income Explanation

CG Oncology's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-31.798	/	0.456
	=	-6,973.25%

During the past 4 years, CG Oncology's highest Pretax Margin was -123.95%. The lowest was -23826.96%. And the median was -13143.02%.

CG Oncology Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of CG Oncology's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618

Website

https://www.cgoncology.com

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.